US Drug Recall Register

FDA Drug Recalls

14,801 recalls, newest first

Class II · Moderate risk Terminated

VERMOX Tablets 100 mg

Reason CGMP Deviations

Profarma Distributors LLC D-1041-2016
Class II · Moderate risk Terminated

tabcin NOCHE

Reason CGMP Deviations

Profarma Distributors LLC D-1040-2016
Class II · Moderate risk Terminated

tabcin ACTIVE M.R. Capsules

Reason CGMP Deviations

Profarma Distributors LLC D-1039-2016
Class II · Moderate risk Terminated

Tazorac

Reason Failed Content Uniformity Specifications.

Allergan Sales, LLC D-1065-2016
Class II · Moderate risk Terminated

Tazorac

Reason Failed Content Uniformity Specifications.

Allergan Sales, LLC NDC 0023-8335-03 D-1064-2016
Class II · Moderate risk Terminated

Coppertone SUNSCREEN LOTION

Reason Labeling; Product Contains Undeclared API (Oxybenzone)

Bayer Health Care LLC NDC 11523-7391-1 D-0977-2016
Class II · Moderate risk Terminated

Bromocriptine Mesylate Capsules USP

Reason Failed impurities/degradation specifications: Out of specification results noticed in related substance test during analysis of 24 months long term (25 degree Celsius /65% RH) stability samples of two batches.

Zydus Pharmaceuticals USA Inc NDC 68382-110-06 D-1491-2016
Class II · Moderate risk Terminated

8 mcg/mL HYDROmorphone HCl and 0.05% Bupivacaine HCl

Reason Presence of Particulate Matter: API contaminated with glass particulate was used to produce sterile injectable drugs.

Pharmedium Services, LLC NDC 61553-310-50 D-1434-2016
Class II · Moderate risk Terminated

6.66 mcg/mL Fentanyl Citrate and 0.22% Bupivacaine HCl

Reason Presence of Particulate Matter: API contaminated with glass particulate was used to produce sterile injectable drugs.

Pharmedium Services, LLC NDC 61553-156-86 D-1433-2016
Class II · Moderate risk Terminated

6.66 mcg/mL Fentanyl Citrate and 0.125% Bupivacaine HCl

Reason Presence of Particulate Matter: API contaminated with glass particulate was used to produce sterile injectable drugs.

Pharmedium Services, LLC NDC 61553-993-86 D-1432-2016
Class II · Moderate risk Terminated

5 mcg/mL HYDROmorphone HCl and 0.125% Bupivacaine HCl

Reason Presence of Particulate Matter: API contaminated with glass particulate was used to produce sterile injectable drugs.

Pharmedium Services, LLC NDC 61553-197-20 D-1431-2016
Class II · Moderate risk Terminated

5 mcg/mL HYDROmorphone HCl and 0.1% Bupivacaine HCl

Reason Presence of Particulate Matter: API contaminated with glass particulate was used to produce sterile injectable drugs.

Pharmedium Services, LLC NDC 61553-233-54 D-1430-2016
Class II · Moderate risk Terminated

5 mcg/mL HYDROmorphone HCl and 0.075% Bupivacaine HCl

Reason Presence of Particulate Matter: API contaminated with glass particulate was used to produce sterile injectable drugs.

Pharmedium Services, LLC NDC 61553-477-50 D-1429-2016
Class II · Moderate risk Terminated

5 mcg/mL HYDROmorphone HCl and 0.0625% Bupivacaine HCl

Reason Presence of Particulate Matter: API contaminated with glass particulate was used to produce sterile injectable drugs.

Pharmedium Services, LLC NDC 61553-483-61 D-1428-2016
Class II · Moderate risk Terminated

5 mcg/mL Fentanyl Citrate and 0.25% Bupivacaine HCl

Reason Presence of Particulate Matter: API contaminated with glass particulate was used to produce sterile injectable drugs.

Pharmedium Services, LLC NDC 61553-200-52 D-1427-2016
Class II · Moderate risk Terminated

5 mcg/mL Fentanyl Citrate and 0.125% Bupivacaine HCl

Reason Presence of Particulate Matter: API contaminated with glass particulate was used to produce sterile injectable drugs.

Pharmedium Services, LLC NDC 61553-140-20 D-1426-2016
Class II · Moderate risk Terminated

5 mcg/mL Fentanyl Citrate and 0.1% Bupivacaine HCl

Reason Presence of Particulate Matter: API contaminated with glass particulate was used to produce sterile injectable drugs.

Pharmedium Services, LLC NDC 61553-257-20 D-1425-206
Class II · Moderate risk Terminated

5 mcg/mL Fentanyl Citrate and 0.075% Bupivacaine HCl

Reason Presence of Particulate Matter: API contaminated with glass particulate was used to produce sterile injectable drugs.

Pharmedium Services, LLC NDC 61553-287-50 D-1424-2016
Class II · Moderate risk Terminated

5 mcg/mL Fentanyl Citrate and 0.0625% Bupivacaine HCl

Reason Presence of Particulate Matter: API contaminated with glass particulate was used to produce sterile injectable drugs.

Pharmedium Services, LLC NDC 61553-135-48 D-1423-2016
Class II · Moderate risk Terminated

5 mcg/mL Fentanyl Citrate and 0.05% Bupivacaine HCl

Reason Presence of Particulate Matter: API contaminated with glass particulate was used to produce sterile injectable drugs.

Pharmedium Services, LLC NDC 61553-256-50 D-1422-2016
Class II · Moderate risk Terminated

5 mcg/mL Fentanyl Citrate and 0.04% Bupivacaine HCl

Reason Presence of Particulate Matter: API contaminated with glass particulate was used to produce sterile injectable drugs.

Pharmedium Services, LLC NDC 61553-809-48 D-1421-2016
Class II · Moderate risk Terminated

4 mcg/mL Fentanyl Citrate and 0.125% Bupivacaine HCl

Reason Presence of Particulate Matter: API contaminated with glass particulate was used to produce sterile injectable drugs.

Pharmedium Services, LLC NDC 61553-214-48 D-1420-2016
Class II · Moderate risk Terminated

4 mcg/mL Fentanyl Citrate and 0.1% Bupivacaine HCl

Reason Presence of Particulate Matter: API contaminated with glass particulate was used to produce sterile injectable drugs.

Pharmedium Services, LLC NDC 61553-983-48 D-1419-2016
Class II · Moderate risk Terminated

4 mcg/mL Fentanyl Citrate and 0.0625% Bupivacaine HCl

Reason Presence of Particulate Matter: API contaminated with glass particulate was used to produce sterile injectable drugs.

Pharmedium Services, LLC NDC 61553-126-50 D-1418-2016